nach oben

Current Infectious Disease Reports

Erschienen in:

01.07.2016 | Transplant and Oncology (M Ison, N Theodoropoulos and S Pegram, Section Editors)

Infectious Triggers of Chronic Lung Allograft Dysfunction

verfasst von: Aric L. Gregson

Erschienen in: Current Infectious Disease Reports | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Survival after lung transplantation is limited in large part due to the high incidence of chronic rejection, known as chronic lung allograft dysfunction (CLAD). Pulmonary infections are a frequent complication in lung transplant recipients, due both to immunosuppressive medications and constant exposure of the lung allograft to the external environment via the airways. Infection is a recognized risk factor for the development of CLAD, and both acute infection and chronic lung allograft colonization with microorganisms increase the risk for CLAD. Acute infection by community acquired respiratory viruses, and the bacteria Pseudomonas aeruginosa and Staphylococcus aureus are increasingly recognized as important risk factors for CLAD. Colonization by the fungus Aspergillus may also augment the risk of CLAD. Fostering this transition from healthy lung to CLAD in each of these infectious episodes is the persistence of an inflammatory lung allograft environment.

1.•

Bridevaux P-O, Aubert J-D, Soccal PM, Mazza-Stalder J, Berutto C, Rochat T, et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax. 2014;69:32–8. Available from: http://dx.doi.org/10.1136/thoraxjnl-2013-203581. This article is the most comprehensive prospective description of CARV occurrence in LTR.

Kaiser L, Aubert J-D, Pache J-C, Deffernez C, Rochat T, Garbino J, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care. 2006;174:1392–9. Available from: http://www.hubmed.org/display.cgi?uids=17008640.

Tapparel C, Cordey S, Junier T, Farinelli L, Van Belle S, Soccal PM, et al. Rhinovirus genome variation during chronic upper and lower respiratory tract infections. PLoS One. 2011;6:e21163. Available from: http://dx.doi.org/10.1371/journal.pone.0021163.

Gerna G, Vitulo P, Rovida F, Lilleri D, Pellegrini C, Oggionni T, et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol. 2006;78:408–16. Available from: http://www.hubmed.org/display.cgi?uids=16419110.

Vilchez RA, McCurry K, Dauber J, Iacono A, Keenan R, Zeevi A, et al. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis. 2001;33:2004–8. Available from: http://dx.doi.org/10.1086/324348.

Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559–66.

Wendt CH, Fox JM, Hertz MI. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant. 1995;14:479–85.

Palmer S Jr, Henshaw NG, Howell DN, Miller SE, Davis RD, Tapson VF. Community respiratory viral infection in adult lung transplant recipients. Chest. 1998;113:944–50.

McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745–53.

10.

Garbino J, Gerbase MW, Wunderli W, Kolarova L, Nicod LP, Rochat T, et al. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest. 2004;125:1033–9.

11.

Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest. 2001;119:1277–80.

12.

Hopkins P, McNeil K, Kermeen F, Musk M, McQueen E, Mackay I, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care. 2008;178:876–81. Available from: http://www.hubmed.org/display.cgi?uids=18658110.

13.

Hayes D Jr, Mansour HM, Kirkby S, Phillips AB. Rapid acute onset of bronchiolitis obliterans syndrome in a lung transplant recipient after respiratory syncytial virus infection. Transpl Infect Dis. 2012;14:548–50. Available from: http://dx.doi.org/10.1111/j.1399-3062.2012.00748.x.

14.

Vilchez R, McCurry K, Dauber J, Iacono A, Keenan R, Griffith B, et al. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation. 2002;73:1075–8.

15.

Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am. J. Transplant. 2005;5:2031–6. Available from: http://www.hubmed.org/display.cgi?uids=15996256

16.

Sayah DM, Koff JL, Leard LE, Hays SR, Golden JA, Singer JP. Rhinovirus and other respiratory viruses exert different effects on lung allograft function that are not mediated through acute rejection. Clin Transplant. 2013;27:E64–71. Available from: http://dx.doi.org/10.1111/ctr.12054.

17.

Vu D-L, Bridevaux P-O, Aubert J-D, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011;11:1071–8. Available from: http://dx.doi.org/10.1111/j.1600-6143.2011.03490.x.

18.

Gottlieb J, Schulz TF, Welte T, Fuehner T, Dierich M, Simon AR, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation. 2009;87:1530–7. Available from: http://www.hubmed.org/display.cgi?uids=19461490.

19.

Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170:181–7. Available from: http://dx.doi.org/10.1164/rccm.200310-1359OC.

20.••

Fisher CE, Preiksaitis CM, Lease ED, Edelman J, Kirby KA, Leisenring WM, et al. Symptomatic respiratory virus infection and chronic lung allograft dysfunction. Clin Infect Dis. 2016;62:313–9. Available from: http://dx.doi.org/10.1093/cid/civ871. Demonstrates the association between CARV, mostly lower tract disease, and subsequent CLAD.

21.

Foronjy RF, Dabo AJ, Cummins N, Geraghty P. Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection. BMC Immunol. 2014;15:41. Available from: http://dx.doi.org/10.1186/s12865-014-0041-4.

22.

Hrincius ER, Liedmann S, Finkelstein D, Vogel P, Gansebom S, Samarasinghe AE, et al. Acute lung injury results from innate sensing of viruses by an eR stress pathway. Cell Rep. 2015;11:1591–603. Available from: http://dx.doi.org/10.1016/j.celrep.2015.05.012.

23.

Thomas NJ, DiAngelo S, Hess JC, Fan R, Ball MW, Geskey JM, et al. Transmission of surfactant protein variants and haplotypes in children hospitalized with respiratory syncytial virus. Pediatr Res. 2009;66:70–3. Available from: http://dx.doi.org/10.1203/PDR.0b013e3181a1d768.

24.

Petersdorf RG, Fusco JJ, Harter DH, Albrink WS. Pulmonary infections complicating asian influenza. AMA Arch Intern Med. 1959;103:262–72.CrossRefPubMed

25.

Ebbert JO, Limper AH. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration. 2005;72:263–9. Available from: http://dx.doi.org/10.1159/000085367.

26.

Marchiori R, Bredt CS de O, Campos MMF de, Negretti F, Duarte PAD. Pandemic influenza a/H1N1: comparative analysis of microscopic lung histopathological findings. Einstein (São Paulo, Brazil). 2012;10:306–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23386009.

27.

Hendrickson CM, Matthay MA. Viral pathogens and acute lung injury: investigations inspired by the sARS epidemic and the 2009 h1N1 influenza pandemic. Seminars in respiratory and critical care medicine. 2013;34:475–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23934716.

28.

Gralinski LE, Bankhead A 3rd, Jeng S, Menachery VD, Proll S, Belisle SE, et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. MBio. 2013;4:e00271–13. Available from: http://dx.doi.org/10.1128/mBio.00271-13.

29.

Fujita J, Ohtsuki Y, Higa H, Azuma M, Yoshinouchi T, Haranaga S, et al. Clinicopathological findings of four cases of pure influenza virus a pneumonia. Intern Med. 2014;53:1333–42. Available from: http://dx.doi.org/10.2169/internalmedicine.53.1174.

30.•

Shino MY, Weigt SS, Li N, Palchevskiy V, Derhovanessian A, Saggar R, et al. CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction. Am J Respir Crit Care Med. 2013;188:1117–25. Available from: http://dx.doi.org/10.1164/rccm.201305-0861OC. Provides a possible mechanistic link between severe CARV infections and CLAD.

31.

Weigt SS, Derhovanessian A, Liao E, Hu S, Gregson AL, Kubak BM, et al. CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction. Am J Transplant. 2012;12:477–84. Available from: http://dx.doi.org/10.1111/j.1600-6143.2011.03859.x.

32.

Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol. 1993;67:5360–6.PubMedPubMedCentral

33.

Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis. 2004;190:1076–83. Available from: http://dx.doi.org/10.1086/422327.

34.

Neurohr C, Huppmann P, Leuchte H, Schwaiblmair M, Bittmann I, Jaeger G, et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant. 2005;5:2982–91. Available from: http://dx.doi.org/ 10.1111/j.1600-6143.2005.01103.x.

35.

Manuel O, Kumar D, Moussa G, Chen MH, Pilewski J, McCurry KR, et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation. 2009;87:719–25. Available from: http://dx.doi.org/10.1097/TP.0b013e3181963262.

36.

Costa C, Delsedime L, Solidoro P, Curtoni A, Bergallo M, Libertucci D, et al. Herpesviruses detection by quantitative real-time polymerase chain reaction in bronchoalveolar lavage and transbronchial biopsy in lung transplant: viral infections and histopathological correlation. Transplant Proc. 2010;42:1270–4. Available from: http://dx.doi.org/10.1016/j.transproceed.2010.03.086.

37.

Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152:761–9. Available from: http://dx.doi.org/10.1059/0003-4819-152-12-201006150-00003.

38.

Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010;181:1391–6. Available from: http://dx.doi.org/10.1164/rccm.200911-1786OC.

39.

Tamm M, Aboyoun CL, Chhajed PN, Rainer S, Malouf MA, Glanville AR. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2004;170:1120–3. Available from: http://dx.doi.org/10.1164/rccm.200310-1405OC

40.

Humbert M, Delattre RM, Fattal S, Rain B, Cerrina J, Dartevelle P, et al. In situ production of interleukin-6 within human lung allografts displaying rejection or cytomegalovirus pneumonia. Transplantation. 1993;56:623–7.

41.

Monti G, Magnan A, Fattal M, Rain B, Humbert M, Mege JL, et al. Intrapulmonary production of rANTES during rejection and cMV pneumonitis after lung transplantation. Transplantation. 1996;61:1757–62.

42.

Weigt SS, Elashoff RM, Keane MP, Strieter RM, Gomperts BN, Xue YY, et al. Altered levels of cC chemokines during pulmonary cMV predict bOS and mortality post-lung transplantation. Am J Transplant. 2008;8:1512–22.CrossRefPubMedPubMedCentral

43.

Engelmann I, Welte T, Fühner T, Simon AR, Mattner F, Hoy L, et al. Detection of epstein-barr virus dNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol. 2009;45:47–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19303808

44.

Mattner F, Hesse N, Fegbeutel C, Strüber M, Gottlieb J, Sohr D, et al. Viremia after lung transplant: a cohort study on risk factors and symptoms associated with detection of epstein-barr virus. Prog Transplant. 2012;22:155–60. Available from: http://dx.doi.org/10.7182/pit2012771

45.

Krumbholz A, Sandhaus T, Göhlert A, Heim A, Zell R, Egerer R, et al. Epstein-barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient. Med Microbiol Immunol. 2010;199:317–22. Available from: http://dx.doi.org/10.1007/s00430-010-0165-y.

46.

De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, et al. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell. 2013;155:1178–87. Available from: http://dx.doi.org/10.1016/j.cell.2013.10.034.

47.

Görzer I, Haloschan M, Jaksch P, Klepetko W, Puchhammer-Stöckl E. Plasma dNA levels of torque teno virus and immunosuppression after lung transplantation. J Heart Lung Transplant. 2014;33:320–3. Available from: http://dx.doi.org/10.1016/j.healun.2013.12.007.

48.

Young JC, Chehoud C, Bittinger K, Bailey A, Diamond JM, Cantu E, et al. Viral metagenomics reveal blooms of anelloviruses in the respiratory tract of lung transplant recipients. Am J Transplant. 2015;15:200–9. Available from: http://dx.doi.org/10.1111/ajt.13031

49.

Solé A, Morant P, Salavert M, Pemán J, Morales P, Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2005;11:359–65.

50.

Hosseini-Moghaddam SM, Chaparro C, Luong M-L, Azad S, Singer LG, Mazzulli T, et al. The effectiveness of culture-directed preemptive anti-aspergillus treatment in lung transplant recipients at one year after transplant. Transplantation. 2015;99:2387–93. Available from: http://dx.doi.org/10.1097/TP.0000000000000743.

51.

Peghin M, Monforte V, Martin-Gomez M-T, Ruiz-Camps I, Berastegui C, Saez B, et al. 10 years of prophylaxis with nebulized liposomal amphotericin b and the changing epidemiology of aspergillus spp. infection in lung transplantation. Transpl Int. 2016;29:51–62. Available from: http://dx.doi.org/10.1111/tri.12679.

52.••

Mansh M, Binstock M, Williams K, Hafeez F, Kim J, Glidden D, et al. Voriconazole exposure and risk of cutaneous squamous cell carcinoma, aspergillus colonization, invasive aspergillosis and death in lung transplant recipients. Am J Transplant. 2016;16:262–70. Available from: http://dx.doi.org/10.1111/ajt.13431. Illustrates the benefits and consequences of long term voriconazole prophylaxis.

53.

Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (tRANSNET). Clin Infect Dis. 2010;50:1101–11. Available from: http://dx.doi.org/10.1086/651262.

54.

Valentine VG, Gupta MR, Jr JEW, Seoane L, Bonvillain RW, Lombard GA, et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2009;28:163–9.CrossRefPubMed

55.

Weigt SS, Elashoff RM, Huang C, Ardehali A, Gregson AL, Kubak B, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant. 2009;9:1903–11. Available from: http://www.hubmed.org/display.cgi?uids=19459819.

56.•

Weigt SS, Copeland CAF, Derhovanessian A, Shino MY, Davis WA, Snyder LD, et al. Colonization with small conidia aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study. Am J Transplant. 2013;13:919–27. Available from: http://dx.doi.org/10.1111/ajt.12131. Demonstrates the differential effect of small and large Aspergillus conidia on CLAD.

57.

Husain S, Paterson DL, Studer S, Pilewski J, Crespo M, Zaldonis D, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008–16. Available from: http://dx.doi.org/10.1111/j.1600-6143.2006.01548.x.

58.

Wang TF, Wang T, Altman R, Eshaghian P, Lynch III JP, Ross DJ, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant. 2009;9:2845–50.CrossRefPubMed

59.

Horvath J, Dummer S, Loyd J, Walker B, Merrill WH, Frist WH. Infection in the transplanted and native lung after single lung transplantation. Chest. 1993;104:681–5.CrossRefPubMed

60.

Aguilar-Guisado M, Givalda J, Ussetti P, Ramos A, Morales P, Blanes M, et al. Pneumonia after lung transplantation in the rESITRA cohort: a multicenter prospective study. Am J Transplant. 2007;7:1989–96.CrossRefPubMed

61.

Valentine VG, Bonvillain RW, Gupta MR, Lombard GA, LaPlace SG, Dhillon GS, et al. Infections in lung allograft recipients: Ganciclovir era. J Heart Lung Transplant. 2008;27:528–35.CrossRefPubMed

62.

Parada MT, Alba A, Sepulveda C. Early and late infections in lung transplantation patients. Transplant Proc. 2010;42:333–5.CrossRefPubMed

63.

Campos S, Caramori M, Teixeira R, Jr JA, Carraro R, Strabelli T, et al. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc. 2008;40:822–4. Available from: http://dx.doi.org/10.1016/j.transproceed.2008.02.049.

64.

Gottlieb J, Mattner F, Weissbrodt H, Dierich M, Fuehner T, Strueber M, et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Resp Med. 2009;103:743–9. Available from: http://dx.doi.org/10.1016/j.rmed.2008.11.015.

65.

Zeglen S, Wojarski J, Wozniak-Grygiel E, Siola M, Jastrzebski D, Kucewicz-Czech E, et al. Frequency of pseudomonas aeruginosa colonizations/infections in lung transplant recipients. Transplant Proc. 2009;41:3222–4.CrossRefPubMed

66.

Gregson AL, Wang X, Injean P, Weigt SS, Shino M, Sayah D, et al. Staphylococcus via an interaction with the eLR+ cXC chemokine eNA-78 is associated with bOS. Am J Transplant. 2015;15:792–9. Available from: http://dx.doi.org/10.1111/ajt.13029.

67.

Gupta MR, Valentine VG, Jr JEW, Lombard GA, LaPlace SG, Seoane L, et al. Clinical spectrum of gram-positive infections in lung transplantation. Transpl Infect Dis. 2009;11:424–31. Available from: http://dx.doi.org/10.1111/j.1399-3062.2009.00422.x.

68.

Mohammed KA, Nasreen N, Ward MJ, Antony VB. Induction of acute pleural inflammation by staphylococcus aureus. i. cD4+ t cells play a critical role in experimental empyema. J Infect Dis. 2000;181:1693–9. Available from: http://dx.doi.org/10.1086/315422.

69.

Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med. 2003;168:628–32. Available from: http://dx.doi.org/10.1164/rccm.200303-447OC.

70.

Bruno TF, Woods DE, Storey DG, Mody CH. Recombinant pseudomonas exoenzyme s and exoenzyme s from pseudomonas aeruginosa dG1 share the ability to stimulate t lymphocyte proliferation. Can. J. Microbiol. 1999;45:607–11. Available from: http://www.hubmed.org/display.cgi?uids=10497789.

71.

Mody CH, Buser DE, Syme RM, Woods DE. Pseudomonas aeruginosa exoenzyme s induces proliferation of human t lymphocytes. Infect. Immun. 1995;63:1800–5. Available from: http://www.hubmed.org/display.cgi?uids=7537248.

72.

Yamamoto S, Nava RG, Zhu J, Huang HJ, Ibrahim M, Mohanakumar T, et al. Cutting edge: pseudomonas aeruginosa abolishes established lung transplant tolerance by stimulating b7 expression on neutrophils. J Immunol. 2012;189:4221–5. Available from: http://dx.doi.org/10.4049/jimmunol.1201683.

73.

Borthwick LA, Sunny SS, Oliphant V, Perry J, Brodlie M, Johnson GE, et al. Pseudomonas aeruginosa accentuates epithelial-to-mesenchymal transition in the airway. Eur Respir J. 2011;37:1237–47. Available from: http://dx.doi.org/10.1183/09031936.00088410.

74.

Dosanjh AK, Elashoff D, Robbins RC. The bronchoalveolar lavage fluid of cystic fibrosis lung transplant recipients demonstrates increased interleukin-8 and elastase and decreased iL-10. J Interf Cytokine Res. 1998;18:851–4.CrossRef

75.

Vos R, Vanaudenaerde BM, Dupont LJ, Raemdonck DEV, Verleden GM. Transient airway colonization is associated with airway inflammation after lung transplantation. Am J Transplant. 2007;7:1278–87.CrossRefPubMed

76.

Vos R, Blondeau K, Vanaudenaerde BM, Mertens V, Raemdonck DEV, Sifrim D, et al. Airway colonization and gastric aspiration after lung transplantation: do birds of a feather flock together? J Heart Lung Transplant. 2008;27:843–9.CrossRefPubMed

77.

Alam DA, Deslee G, Tournois C, Lamkhioued B, Lebargy F, Merten M, et al. Impaired interleukin-8 chemokine secretion by staphylococcus aureus-activated epithelium and t-cell chemotaxis in cystic fibrosis. Am J Resp Cell Mol. 2010;42:644–50. Available from: http://dx.doi.org/10.1165/rcmb.2008-0021OC.

78.

Takata H, Tomiyama H, Fujiwara M, Kobayashi N, Takiguchi M. Cutting edge: expression of chemokine receptor cXCR1 on human effector cD8+ t cells. J. Immunol. 2004;173:2231–5. Available from: http://www.hubmed.org/display.cgi?uids=15294933.

79.

Rossi GA, Sacco O, Balbi B, Oddera S, Mattioni T, Corte G, et al. Human ciliated bronchial epithelial cells: expression of the hLA-dR antigens and of the hLA-dR alpha gene, modulation of the hLA-dR antigens by gamma-interferon and antigen-presenting function in the mixed leukocyte reaction. Am. J. Respir. Cell Mol. Biol. 1990;3:431–9. Available from: http://www.hubmed.org/display.cgi?uids=2145880.

80.

Arbustini E, Morbini P, Diegoli M, Grasso M, Fasani R, Vitulo P, et al. Coexpression of aspartic proteinases and human leukocyte antigen-dR in human transplanted lung. Am. J. Pathol. 1994;145:310–21. Available from: http://www.hubmed.org/display.cgi?uids=8053491.

81.

Saunders NA, Smith RJ, Jetten AM. Differential responsiveness of human bronchial epithelial cells, lung carcinoma cells, and bronchial fibroblasts to interferon-gamma in vitro. Am J Respir Cell Mol Biol. 1994;11:147–52. Available from: http://dx.doi.org/10.1165/ajrcmb.11.2.8049075.

82.

Haynes LD, Bushkin Y, Love RB, Burlingham WJ. Interferon-gamma drives the metalloproteinase-dependent cleavage of hLA class i soluble forms from primary human bronchial epithelial cells. Hum Immunol. 2002;63:893–901. Available from: http://www.hubmed.org/display.cgi?uids=12368042.

83.

Gregson AL, Hoji A, Injean P, Poynter ST, Briones C, Palchevskiy V, et al. Altered exosomal rNA profiles in bronchoalveolar lavage from lung transplants with acute rejection. Am J Respir Crit Care Med. 2015;192:1490–503. Available from: http://dx.doi.org/10.1164/rccm.201503-0558OC.

84.

Rosenstiel P, Sina C, End C, Renner M, Lyer S, Till A, et al. Regulation of dMBT1 via nOD2 and tLR4 in intestinal epithelial cells modulates bacterial recognition and invasion. Journal of immunology (Baltimore, Md. : 1950). 2007;178:8203–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17548659.

85.

Gazdhar A, Susuri N, Hostettler K, Gugger M, Knudsen L, Roth M, et al. HGF expressing stem cells in usual interstitial pneumonia originate from the bone marrow and are antifibrotic. PLoS One. 2013;8:e65453. Available from: http://dx.doi.org/10.1371/journal.pone.0065453.

86.

Borthwick LA, Barron L, Hart KM, Vannella KM, Thompson RW, Oland S, et al. Macrophages are critical to the maintenance of iL-13-dependent lung inflammation and fibrosis. Mucosal Immunol. 2016;9:38–55. Available from: http://dx.doi.org/10.1038/mi.2015.34.

87.

Vos R, Vanaudenaerde BM, Geudens N, Dupont LJ, Raemdonck DEV, Verleden GM. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J. 2008;31:1037–45.CrossRefPubMed

88.

Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008;85:771–4.CrossRefPubMed

89.

Willner DL, Hugenholtz P, Yerkovich ST, Tan ME, Daly JN, Lachner N, et al. Reestablishment of recipient-associated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2013;187:640–7. Available from: http://dx.doi.org/10.1164/rccm.201209-1680OC.

90.

Vos R, Vanaudenaerde BM, De Vleeschauwer SI, Van Raemdonck DE, Dupont LJ, Verleden GM. De novo or persistent pseudomonal airway colonization after lung transplantation: importance for bronchiolitis obliterans syndrome? Transplantation. 2008;86:624–5; author reply 635–6. Available from: http://dx.doi.org/10.1097/TP.0b013e318182295d.

91.

Cobb LM, Mychaleckyj JC, Wozniak DJ, Lopez-Boado YS. Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease. J Immunol. 2004;173:5659–70. Available from: http://www.hubmed.org/display.cgi?uids=15494517.

92.

Perez A, Davis PB. Gene profile changes after pseudomonas aeruginosa exposure in immortalized airway epithelial cells. J. Struct. Funct. Genomics. 2004;5:179–94. Available from: http://www.hubmed.org/display.cgi?uids=15263834

93.

Moser C, Van Gennip M, Bjarnsholt T, Jensen PØ, Lee B, Hougen HP, et al. Novel experimental pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. APMIS. 2009;117:95–107. Available from: http://dx.doi.org/10.1111/j.1600-0463.2008.00018.x.

94.

Aaron SD, Vandemheen KL, Ramotar K, Giesbrecht-Lewis T, Tullis E, Freitag A, et al. Infection with transmissible strains of pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA. 2010;304:2145–53.CrossRefPubMed

95.

Shteinberg M, Raviv Y, Bishara J, Stein N, Rosengarten D, Bakal I, et al. The impact of fluoroquinolone resistance of gram-negative bacteria in respiratory secretions on the outcome of lung transplant (non-cystic fibrosis) recipients. Clin Transplant. 2012;26:884–90. Available from: http://dx.doi.org/10.1111/j.1399-0012.2012.01665.x.

96.

Walter S, Gudowius P, Bosshammer J, Romling U, Weissbrodt H, Schurmann W, et al. Epidemiology of chronic pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax. 1997;52:318–21.CrossRefPubMedPubMedCentral

97.••

Gregson AL, Wang X, Weigt SS, Palchevskiy V, Lynch JP 3rd, Ross DJ, et al. Interaction between pseudomonas and cXC chemokines increases risk of bOS and death in lung transplantation. Am J Respir Crit Care Med. 2013;187:518–26. Available from: http://dx.doi.org/10.1164/rccm.201207-1228OC. Details the effects of infections, such as Aspergillus and Pseudomonas, post-lung transplantation in a state dependent manner.

Titel: Infectious Triggers of Chronic Lung Allograft Dysfunction
verfasst von: Aric L. Gregson
Publikationsdatum: 01.07.2016
Verlag: Springer US
Erschienen in: Current Infectious Disease Reports / Ausgabe 7/2016
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-016-0529-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Spondylitis ankylosans | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Infectious Triggers of Chronic Lung Allograft Dysfunction

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin